Compare SGC & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SGC | RNA |
|---|---|---|
| Founded | 1920 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 181.8M | 209.5M |
| IPO Year | 1994 | 2025 |
| Metric | SGC | RNA |
|---|---|---|
| Price | $12.96 | $11.55 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 20 |
| Target Price | $16.00 | ★ $69.26 |
| AVG Volume (30 Days) | 36.0K | ★ 162.8K |
| Earning Date | 05-04-2026 | 01-01-0001 |
| Dividend Yield | ★ 4.93% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $566,184,000.00 | N/A |
| Revenue This Year | $3.23 | $88.12 |
| Revenue Next Year | $3.82 | $18.11 |
| P/E Ratio | $213.67 | ★ N/A |
| Revenue Growth | ★ 0.09 | N/A |
| 52 Week Low | $8.30 | $11.77 |
| 52 Week High | $13.78 | $73.06 |
| Indicator | SGC | RNA |
|---|---|---|
| Relative Strength Index (RSI) | 60.35 | 29.01 |
| Support Level | $9.79 | N/A |
| Resistance Level | $13.78 | $14.05 |
| Average True Range (ATR) | 0.64 | 0.50 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 78.80 | 3.95 |
Superior Group Of Companies Inc designs apparel products. The company operates through three segments: i) The Branded Products segment, under the brands BAMKO and HPI, produces and sells customized merchandising solutions, promotional products, and branded uniform programs. ii) The Healthcare Apparel segment, under the brands Wink and Fashion Seal Healthcare, manufactures and sells healthcare apparel including scrubs, lab coats, protective apparel, and patient garments. iii) The Contact Centers segment, through The Office Gurus entities, provides outsourced, nearshore, and onshore business process outsourcing (BPO), contact center, and call-center support services to customers in North America. The majority of the company's revenue is derived from the Branded Products segment.
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.